ZA202001880B - Compositions and methods for treating brain injury - Google Patents
Compositions and methods for treating brain injuryInfo
- Publication number
- ZA202001880B ZA202001880B ZA2020/01880A ZA202001880A ZA202001880B ZA 202001880 B ZA202001880 B ZA 202001880B ZA 2020/01880 A ZA2020/01880 A ZA 2020/01880A ZA 202001880 A ZA202001880 A ZA 202001880A ZA 202001880 B ZA202001880 B ZA 202001880B
- Authority
- ZA
- South Africa
- Prior art keywords
- compositions
- methods
- brain injury
- treating brain
- treating
- Prior art date
Links
- 208000029028 brain injury Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762559113P | 2017-09-15 | 2017-09-15 | |
| US201762584343P | 2017-11-10 | 2017-11-10 | |
| US201862658758P | 2018-04-17 | 2018-04-17 | |
| PCT/US2018/051331 WO2019055913A1 (en) | 2017-09-15 | 2018-09-17 | COMPOSITIONS AND METHODS FOR TREATMENT OF BRAIN INJURY |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202001880B true ZA202001880B (en) | 2022-06-29 |
Family
ID=65723435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2020/01880A ZA202001880B (en) | 2017-09-15 | 2020-03-24 | Compositions and methods for treating brain injury |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11628160B2 (enExample) |
| EP (1) | EP3681871A4 (enExample) |
| JP (2) | JP2020534274A (enExample) |
| KR (1) | KR102790657B1 (enExample) |
| CN (1) | CN111295373B (enExample) |
| AU (1) | AU2018333051B2 (enExample) |
| BR (1) | BR112020005107A2 (enExample) |
| CA (1) | CA3075759A1 (enExample) |
| IL (1) | IL273228B2 (enExample) |
| MX (1) | MX2020002762A (enExample) |
| MY (1) | MY208313A (enExample) |
| TW (1) | TW201919625A (enExample) |
| WO (1) | WO2019055913A1 (enExample) |
| ZA (1) | ZA202001880B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012003436A1 (en) | 2010-07-01 | 2012-01-05 | Azevan Pharmaceuticals, Inc. | Methods for treating post traumatic stress disorder |
| CA2944211C (en) | 2014-03-28 | 2022-10-04 | Azevan Pharmaceuticals, Inc. | Compositions and methods for treating neurodegenerative diseases |
| CN108883104A (zh) * | 2016-03-30 | 2018-11-23 | 森泰克希斯公司 | 用于在治疗成熟脑损伤中使用的mGluR5的负性变构调节剂 |
| EP3681871A4 (en) * | 2017-09-15 | 2021-05-26 | Azevan Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF A BRAIN DAMAGE |
| US11583538B2 (en) | 2019-04-08 | 2023-02-21 | Venenum Biodesign, LLC | Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors |
| WO2022075974A1 (en) * | 2020-10-06 | 2022-04-14 | Venenum Biodesign, LLC | Cyclic trex1 inhibitors |
| CN115350186A (zh) * | 2022-08-31 | 2022-11-18 | 中国人民解放军军事科学院军事医学研究院 | Sxr246在制备治疗创伤性脑损伤及预后不良药物中的应用 |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1422263A (en) | 1973-01-30 | 1976-01-21 | Ferrosan As | 4-phenyl-piperidine compounds |
| US4314081A (en) | 1974-01-10 | 1982-02-02 | Eli Lilly And Company | Arloxyphenylpropylamines |
| NL7503310A (nl) | 1975-03-20 | 1976-09-22 | Philips Nv | Verbindingen met antidepressieve werking. |
| US4576753A (en) | 1975-10-06 | 1986-03-18 | Fujisawa Pharmaceutical Co., Ltd. | Azetidinone compounds and processes for preparation thereof |
| GB1526331A (en) | 1976-01-14 | 1978-09-27 | Kefalas As | Phthalanes |
| US4341698A (en) | 1979-06-21 | 1982-07-27 | Richardson-Merrell Inc. | Enkaphalin derivatives |
| US4536518A (en) | 1979-11-01 | 1985-08-20 | Pfizer Inc. | Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine |
| JPS56125361A (en) | 1980-03-07 | 1981-10-01 | Sagami Chem Res Center | Azetidinone compound |
| JPS6033439B2 (ja) | 1980-03-07 | 1985-08-02 | 財団法人相模中央化学研究所 | ジペプチドの製造方法 |
| FR2508035A1 (fr) | 1981-06-23 | 1982-12-24 | Fabre Sa Pierre | Derives d'aryl-1-aminomethyl-2 cyclopropanes carboxamides (z), leur preparation et leur application en tant que medicaments utiles dans le traitement des troubles du systeme nerveux central |
| US4761501A (en) | 1983-10-26 | 1988-08-02 | American Home Products Corporation | Substituted phenylacetamides |
| US4751299A (en) | 1983-11-18 | 1988-06-14 | Takeda Chemical Industries, Ltd. | Optically active β-lactams and method of their production |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4734498A (en) | 1986-07-10 | 1988-03-29 | Eli Lilly And Company | 3β-succinimidoazetidinones as chiral intermediates |
| US4772694A (en) | 1986-07-24 | 1988-09-20 | Eli Lilly And Company | Chiral 3-(1,2,5-trisubstituted imidazolidinone) azetidinone antibiotic intermediates |
| US4956388A (en) | 1986-12-22 | 1990-09-11 | Eli Lilly And Company | 3-aryloxy-3-substituted propanamines |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| JP3208139B2 (ja) | 1990-10-02 | 2001-09-10 | ワーナー−ランバート・コンパニー | アンギオテンシン▲ｉｉ▼アンタゴニスト |
| GB9204001D0 (en) | 1992-02-25 | 1992-04-08 | Jacobs Suchard Ag | Process for producing reduced fat nuts |
| US5246943A (en) | 1992-05-19 | 1993-09-21 | Warner-Lambert Company | Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties |
| AU4713293A (en) | 1992-07-13 | 1994-01-31 | Merck Sharp & Dohme Limited | Heterocyclic amide derivatives as tachykinin derivatives |
| EP0655055B1 (en) | 1992-08-13 | 2000-11-29 | Warner-Lambert Company | Tachykinin antagonists |
| FR2696178B1 (fr) | 1992-09-30 | 1994-12-30 | Sanofi Elf | Amides basiques quaternaires, procédé pour leur préparation et compositions pharmaceutiques en contenant. |
| JP3424174B2 (ja) | 1993-05-06 | 2003-07-07 | メレルダウファーマス−ティカルズ インコーポレイテッド | タキキニン拮抗剤として有用な置換ピロリジン−３−イル−アルキル−ピペリジン類 |
| US5512563A (en) | 1993-07-29 | 1996-04-30 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
| US5759865A (en) | 1995-05-03 | 1998-06-02 | Eli Lilly And Company | Combinatorial process for synthesizing azetidinone analogs |
| GB9511694D0 (en) | 1995-06-09 | 1995-08-02 | Fujisawa Pharmaceutical Co | Benzamide derivatives |
| JP4212112B2 (ja) | 1996-02-23 | 2009-01-21 | イーライ・リリー・アンド・カンパニー | 非ペプチジルバソプレッシンＶ１ａアンタゴニスト |
| HUP0000288A3 (en) | 1996-12-13 | 2001-04-28 | Lilly Co Eli | Azetidinone derivatives as inhibitors of the enzymatic activity of psa, intermediates, process for their preparation and pharmaceutical compositions thereof |
| EP0987266A4 (en) | 1997-03-31 | 2000-07-26 | Wakamoto Pharma Co Ltd | BIPHENYL DERIVATIVES AND MEDICINAL COMPOSITIONS |
| SI1000062T1 (en) | 1997-07-30 | 2004-12-31 | Wyeth | Tricyclic vasopressin agonists |
| US6403632B1 (en) | 2000-03-01 | 2002-06-11 | Bristol Myers Squibb Pharma Co | Lactam metalloprotease inhibitors |
| CA2307820C (en) | 1997-10-27 | 2007-04-24 | Dr. Reddy's Research Foundation | Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them |
| US6627625B1 (en) | 1999-08-16 | 2003-09-30 | Revaax Pharmaceuticals, Llc | Treatment of behavioral disorders with β-lactam compounds |
| GB0019006D0 (en) | 2000-08-04 | 2000-09-20 | Astrazeneca Ab | Novel compounds |
| AU2002342045C1 (en) | 2001-10-12 | 2009-07-30 | Azevan Pharmaceuticals, Inc. | Beta-lactamyl vasopressin Vla antagonists |
| AU2002359761A1 (en) | 2001-12-18 | 2003-06-30 | Invenux, Inc. | Antibiotic compounds |
| US7135479B2 (en) | 2002-09-12 | 2006-11-14 | Wyeth | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans |
| GB0224919D0 (en) | 2002-10-25 | 2002-12-04 | Pfizer Ltd | Triazole compounds useful in therapy |
| EP2292620A3 (en) | 2003-07-14 | 2011-06-22 | Arena Pharmaceuticals, Inc. | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prohylaxis and treatment of disorders related thereto |
| US20060281728A1 (en) | 2003-10-03 | 2006-12-14 | Guillon Christophe D | 3-Substituted beta-lactamyl vasopressin v1a antagonists |
| US7745630B2 (en) | 2003-12-22 | 2010-06-29 | Justin Stephen Bryans | Triazolyl piperidine arginine vasopressin receptor modulators |
| EP1632494A1 (en) | 2004-08-24 | 2006-03-08 | Ferring B.V. | Vasopressin v1a antagonists |
| EP1669776A1 (de) | 2004-12-11 | 2006-06-14 | Leica Geosystems AG | Handhaltbares Vermessungsgerät und Vermessungsverfahren für ein solches Vermessungsgerät |
| FR2881744B1 (fr) | 2005-02-09 | 2007-04-27 | Sanofi Aventis Sa | Derives de n-[(4,5-diphenyl-2-thienyl)methyl]amine, leur preparation et leur application en therapeutique |
| CA2601709C (en) | 2005-03-22 | 2017-02-14 | Azevan Pharmaceuticals, Inc. | Beta-lactamylalkanoic acids |
| US20080234252A1 (en) | 2005-05-18 | 2008-09-25 | Pfizer Inc | Compounds Useful in Therapy |
| AU2006270039B2 (en) | 2005-07-19 | 2013-07-04 | Azevan Pharmaceuticals, Inc. | Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonists |
| WO2007109615A2 (en) | 2006-03-21 | 2007-09-27 | Azevan Pharmaceuticals, Inc. | β -LACTAMYL VASOPRESSIN V2 ANTAGONISTS |
| US20100016274A1 (en) | 2006-09-14 | 2010-01-21 | Koppel Gary A | Beta-lactam cannabinoid receptor modulators |
| EP2076517A1 (en) | 2006-09-22 | 2009-07-08 | Janssen Pharmaceutica N.V. | Spiro benzazepines as vasopressin antagonists |
| EP2078022B1 (en) * | 2006-09-22 | 2011-11-09 | Janssen Pharmaceutica N.V. | Spiro benzazepines used as vasopressin antagonists |
| US8362037B2 (en) | 2007-03-23 | 2013-01-29 | Array Biopharma, Inc. | 2-aminopyridine analogs as glucokinase activators |
| FR2927625B1 (fr) | 2008-02-19 | 2010-03-12 | Sanofi Aventis | Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique |
| FR2930249B1 (fr) | 2008-04-21 | 2010-05-14 | Sanofi Aventis | Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique. |
| WO2012003436A1 (en) * | 2010-07-01 | 2012-01-05 | Azevan Pharmaceuticals, Inc. | Methods for treating post traumatic stress disorder |
| CN102156420B (zh) | 2010-12-23 | 2012-11-07 | 天津职业技术师范大学 | 加快从计算机下载数据到单片机目标存储器的装置 |
| US20150376198A1 (en) * | 2013-02-18 | 2015-12-31 | The Scripps Research Institute | Modulators of vasopressin receptors with therapeutic potential |
| CA2944211C (en) | 2014-03-28 | 2022-10-04 | Azevan Pharmaceuticals, Inc. | Compositions and methods for treating neurodegenerative diseases |
| EP3681871A4 (en) * | 2017-09-15 | 2021-05-26 | Azevan Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF A BRAIN DAMAGE |
-
2018
- 2018-09-17 EP EP18855876.1A patent/EP3681871A4/en active Pending
- 2018-09-17 JP JP2020515077A patent/JP2020534274A/ja active Pending
- 2018-09-17 TW TW107132685A patent/TW201919625A/zh unknown
- 2018-09-17 WO PCT/US2018/051331 patent/WO2019055913A1/en not_active Ceased
- 2018-09-17 CN CN201880070936.8A patent/CN111295373B/zh active Active
- 2018-09-17 BR BR112020005107-1A patent/BR112020005107A2/pt unknown
- 2018-09-17 MX MX2020002762A patent/MX2020002762A/es unknown
- 2018-09-17 AU AU2018333051A patent/AU2018333051B2/en active Active
- 2018-09-17 CA CA3075759A patent/CA3075759A1/en active Pending
- 2018-09-17 US US16/646,744 patent/US11628160B2/en active Active
- 2018-09-17 KR KR1020207010875A patent/KR102790657B1/ko active Active
- 2018-09-17 IL IL273228A patent/IL273228B2/en unknown
- 2018-09-17 MY MYPI2020001313A patent/MY208313A/en unknown
-
2020
- 2020-03-24 ZA ZA2020/01880A patent/ZA202001880B/en unknown
-
2023
- 2023-04-17 US US18/135,225 patent/US20240115553A1/en not_active Abandoned
- 2023-09-25 JP JP2023161532A patent/JP7699634B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020534274A (ja) | 2020-11-26 |
| JP2023179559A (ja) | 2023-12-19 |
| KR20200071075A (ko) | 2020-06-18 |
| RU2020110038A3 (enExample) | 2021-10-15 |
| US20240115553A1 (en) | 2024-04-11 |
| CN111295373A (zh) | 2020-06-16 |
| US20200276167A1 (en) | 2020-09-03 |
| WO2019055913A1 (en) | 2019-03-21 |
| IL273228B1 (en) | 2024-12-01 |
| EP3681871A4 (en) | 2021-05-26 |
| MY208313A (en) | 2025-04-30 |
| KR102790657B1 (ko) | 2025-04-02 |
| US11628160B2 (en) | 2023-04-18 |
| BR112020005107A2 (pt) | 2020-11-03 |
| RU2020110038A (ru) | 2021-10-15 |
| MX2020002762A (es) | 2020-09-17 |
| TW201919625A (zh) | 2019-06-01 |
| CA3075759A1 (en) | 2019-03-21 |
| EP3681871A1 (en) | 2020-07-22 |
| JP7699634B2 (ja) | 2025-06-27 |
| AU2018333051B2 (en) | 2024-03-21 |
| IL273228A (en) | 2020-04-30 |
| IL273228B2 (en) | 2025-04-01 |
| AU2018333051A1 (en) | 2020-03-26 |
| CN111295373B (zh) | 2024-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2578539B (en) | Compositions and methods for preventing or treating muscle conditions | |
| IL269637A (en) | Preparations and methods for the treatment of synovial diseases | |
| IL253728A0 (en) | Methods and preparations for diagnosing brain damage or neurodegeneration | |
| ZA202001880B (en) | Compositions and methods for treating brain injury | |
| IL251215A0 (en) | Cannabinoid preparation and method for treating pain | |
| IL260352B (en) | Methods and preparations for the treatment of neurological disease | |
| IL293712B1 (en) | Methods for treating mild brain injury | |
| PL3261644T3 (pl) | Kompozycje i sposoby leczenia degradacji siatkówki | |
| GB201714392D0 (en) | Methods and devices for treating glaucoma | |
| IL270114B1 (en) | Methods and compounds for the treatment of neurological diseases | |
| IL262825A (en) | Tetrahydropyridine and tetrahydropyrimidine substances, preparations containing them and their use for pain treatment | |
| IL271256A (en) | Preparations and methods for the treatment of teopathy | |
| PL3717011T3 (pl) | Sposób leczenia lub zapobiegania uszkodzeniu niedokrwienno- reperfuzyjnemu | |
| SG11201704829QA (en) | Methods and compositions for treating brain diseases | |
| SMT202200494T1 (it) | Composizioni e metodi per il trattamento delle ferite | |
| IL276577A (en) | Methods for treating cardiac injury | |
| SG10201706291TA (en) | Composition And Method For Treating Skin Conditions | |
| IL269743A (en) | Methods and preparations for the treatment of disease related to the retina with CCR-3 inhibitor inventions | |
| PL3651749T3 (pl) | Sposób leczenia urazowego uszkodzenia mózgu | |
| IL250658A0 (en) | Methods for treating mild brain injury | |
| IL250114A0 (en) | Methods and compositions for the treatment of hiv-related diseases | |
| HUE068710T2 (hu) | NK1-antagonista kombináció és eljárás szinukleinopátia kezelésére | |
| PT3519050T (pt) | Composições para o tratamento de condições oftálmicas | |
| IL255012A0 (en) | Preparations and methods for treating skin conditions | |
| SG11202005278PA (en) | Compounds for treating eye diseases and methods thereof |